Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by juniper88on Nov 13, 2018 9:18am

119 Views

Post# 28964162

RE:RE:RE:RE:RE:RE:RE:RE:RE:THaimed or TH ?

Wow, are you saying only 1000 to 1300 patients on Trograzo in the end (i.e., peak) ? Again that would be extremely disappointing. Egrifta is thought of as cosmetic by way, it doesn't work in about 30% of the patients, it has a very high turn over. Yes, doctors will continue to try combinations of old drugs that have worked for them in the past, but eventually patients will go on it. And once on should stay on for life. I don't see TH reaching $26/share as you wrote in a couple of years with such a poor adoption.

Bullboard Posts

Investors eye Australian gold mining projects amid promising developments